Legend Biotech Corporation American Depositary Shares

A study of CARVYKTI® demonstrated lasting treatment-free remissions in 80% of standard-risk multiple myeloma patients when used as early as second-line therapy, with improved immune fitness potentially correlating with longer progression-free survival.

Shares of cell therapy company Legend Biotech Corp (NASDAQ:LEGN) were trading lower on Monday, after being among the top pharma gainers in the first week of June. The company's Carvykti drug is likely to return to growth and revive investor enthusiasm, according to Truist Securities. The Legend Biotech Analyst: Asthika Goonewardene initiated cove...

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bristol Myers Squibb’s cell therapy Breyanzi won FDA approval Thursday for treatment of a common type of leukemia.

Bristol-Myers Squibb is a well-known blue-chip stock with a dividend yield exceeding 4.6%. Read why I'm rating BMY stock a Buy at this point.